LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Rocket Pharmaceuticals Inc

Suletud

SektorTervishoid

3.32 -1.78

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.31

Max

3.52

Põhinäitajad

By Trading Economics

Sissetulek

-7.6M

-69M

Kasumimarginaal

-656.728

Töötajad

299

EBITDA

-8M

-66M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+155.75% upside

Turustatistika

By TradingEconomics

Turukapital

61M

393M

Eelmine avamishind

5.1

Eelmine sulgemishind

3.32

Uudiste sentiment

By Acuity

50%

50%

172 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Rocket Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. aug 2025, 12:08 UTC

Suurimad hinnamuutused turgudel

Rocket Pharma Shares Jump After FDA Lifts Clinical Hold on Danon Phase 2 Trial

27. mai 2025, 12:05 UTC

Suurimad hinnamuutused turgudel

Rocket Pharmaceuticals Shares Down as Trial Patient Dies of Complications

Võrdlus sarnastega

Hinnamuutus

Rocket Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

155.75% tõus

12 kuu keskmine prognoos

Keskmine 8.67 USD  155.75%

Kõrge 19 USD

Madal 2 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Rocket Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

16 ratings

8

Osta

7

Hoia

1

Müü

Tehniline skoor

By Trading Central

6.21 / 7.86Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

172 / 372 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.